TP53 and myeloid sarcoma: TP53 mutations were exclusively present in some MS patients at the MS site and not in the bone marrow, and though not statistically significant, primarily due to lower sample size, they may define another subset of MS patients associated with a poor prognosis, similar to what is observed in TP53-mutated AML [108].